155 completed, 33 unknown, 25 terminated, 10 recruiting. 64 Phase 2, 51 Phase 3, 38 Phase 1, 35 Phase 4, 28 Not applicable.
Follow Choroidal Neovascularization: new trials by email Literature Review of Choroidal Neovascularization trials Research Report on Choroidal Neovascularization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety Eyelid Speculum Retraction, Cotton-Tipped Applicator Retraction - Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema | Not applicable | Active not recruiting | Jakkrit Juhong | 129 | 2026-09-09 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-09-01 | 2026-09-10 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) Aflibercept Intravitreous Injection - Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD) | Phase 4 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 174 | 2026-01-01 | 2026-01-26 |
| Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization Intravitreal faricimab injection - Age-related Macular Degeneration (ARMD), Choroidal Neovascularization | Phase 4 | Not yet recruiting | Kim's Eye Hospital | 30 | 2025-09-23 | 2025-09-23 |
| Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization | Phase 4 | Recruiting | Hospital Authority, Hong Kong | 40 | 2025-08-21 | 2025-10-01 |
| Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy | Phase 4 | Recruiting | Association for Innovation and Biomedical Research on Light and Image | 120 | 2025-08-06 | 2026-02-06 |
| AVIGA3 (Cohort 2.0) Amsler Grid, AVIGA - Maculopathy | Not applicable | Recruiting | Tan Tock Seng Hospital | 60 | 2025-06-16 | 2026-06-24 |
| The Treatment Burden of Myopic Choroidal Neovascularization anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization - Myopic Choroidal Neovascularisation, Anti-VEGF Treatment | Not yet recruiting | Policlinico Gaspare Rodolico - San Marco Catania | 100 | 2025-06-01 | 2025-06-06 | |
| Effect of Video Viewing on Intravitreal Injection Experience Procedure video viewing - Age Related Macular Degeneration, Diabetic Retinopathy | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 182 | 2025-05-05 | 2025-06-03 |
| An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings With fundus diseases, Without fundus diseases - Retinal Diseases, Choroidal Disease | Not yet recruiting | Zhongshan Ophthalmic Center, Sun Yat-sen University | 9999 | 2025-05-01 | 2025-04-09 | |
| Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment Aflibercept 8mg - Age-related Macular Degeneration (ARMD) | Phase 4 | Completed | Kim's Eye Hospital | 35 | 2024-10-21 | 2026-07-16 |
| Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization Intravitreal injection of anti-VEGF - Choroidal Neovascularization | Unknown | Beijing Hospital | 80 | 2024-02-10 | 2024-02-07 | |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter - Macular Degeneration Choroidal Neovascularization | Completed | Federico II University | 50 | 2023-07-01 | 2024-05-22 | |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Impact of Non-Exudative Type 1 MNV on AMD Progression Age-Related Macular Degeneration, Neovascularization, Choroidal | Active not recruiting | University of Utah | 73 | 2023-01-30 | 2025-12-17 |
Showing 20 of 245. Sign in to see all of them.
Macular Degeneration (139) · Polypoidal Choroidal Vasculopathy (50) · Wet Macular Degeneration (17) · Diabetic Retinopathy (12) · Eye Diseases (12) · Retinal Diseases (12) · Geographic Atrophy (11) · Retinal Vein Occlusion (10) · Macular Edema (9) · Myopia, Degenerative (9) · Vision Disorders (9) · Angioid Streaks (8) · Retinal Degeneration (8) · Central Serous Chorioretinopathy (5)
Metaplasia (245) · Pathologic Processes (245) · Pathological Conditions, Signs and Symptoms (245) · Uveal Diseases (245) · Choroid Diseases (243) · Neovascularization, Pathologic (241) · Eye Diseases (233) · Retinal Diseases (155) · Retinal Degeneration (139) · Cardiovascular Diseases (25) · Vascular Diseases (23) · Nervous System Diseases (16) · Endocrine System Diseases (13) · Refractive Errors (13)
Ranibizumab (68) · aflibercept (31) · Verteporfin (20) · Bevacizumab (18) · brolucizumab (9) · Intravitreal Injections (7) · salicylhydroxamic acid (7) · Triamcinolone Acetonide (6) · Dexamethasone (5) · Photochemotherapy (5) · faricimab (5) · KH902 fusion protein (4) · pazopanib (4) · E10030 aptamer (3) · Fluorescein Angiography (3)
Novartis Pharmaceuticals (22) · National Eye Institute (NEI) (11) · Novartis (8) · Notal Vision Ltd. (7) · Medical University of Vienna (6) · Ophthotech Corporation (6) · GlaxoSmithKline (5) · Johns Hopkins University (5) · Singapore National Eye Centre (5) · Alcon Research (4) · Allergan (4) · Bayer (4) · Chengdu Kanghong Biotech Co., Ltd. (4) · Kim's Eye Hospital (4) · Asociación para Evitar la Ceguera en México (3)
United States (97) · Italy (26) · South Korea (26) · France (23) · China (20) · Spain (19) · Germany (18) · United Kingdom (16) · Switzerland (15) · Australia (14) · Israel (14) · Portugal (13) · Canada (12) · Austria (11) · Singapore (11)
Andrii MD Korol, PhD (3) · Chong-Lye Ang, FRCOphth (2) · Christian Pruente, MD (2) · Dennis M. Marcus, M.D. (2) · Gabriela Burian, MD (2) · Gregg T Kokame, MD, MMM (2) · Jae Hui Kim, M.D. (2)
PMID 30957581, PMID 30986442, PMID 19726427, PMID 22426346, PMID 23084240, PMID 24113783, PMID 32374423, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 11071039, PMID 11297486, PMID 11642370, PMID 11741106, PMID 12707595, PMID 12967792, PMID 14557174, PMID 15013874, PMID 16019682, PMID 16687455, PMID 16765697, PMID 16897221, PMID 17188044, PMID 17675159, PMID 18046222, PMID 18054887, PMID 18301024, PMID 1850220, PMID 18682970, PMID 19029035, PMID 19184312, PMID 19211094, PMID 1922252, PMID 19365036, PMID 19427992, PMID 19506188, PMID 19592101, PMID 19643495, PMID 20110127, PMID 20375343, PMID 20609706, PMID 20827138, PMID 20847709, PMID 21358461, PMID 21526923, PMID 21555610, PMID 21704964, PMID 21826150, PMID 22150050
2019 (4), 2009 (2), 2014 (2), R01EY019112 (1), R01EY033365 (1), U10EY017823 (1)